{
    "clinical_study": {
        "@rank": "6464", 
        "acronym": "HEAT", 
        "arm_group": [
            {
                "arm_group_label": "Extended Hypofractionation Radiotherapy (EHRT)", 
                "arm_group_type": "Experimental", 
                "description": "A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique."
            }, 
            {
                "arm_group_label": "Accelerated Hypofractionation Radiotherapy (AHRT)", 
                "arm_group_type": "Active Comparator", 
                "description": "A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques."
            }
        ], 
        "brief_summary": {
            "textblock": "Accelerated Hypofractionation Radiotherapy for prostate cancer of 36.25 Gy delivered in 5\n      fractions will not be inferior to the standard treatment of 70.2 Gy given in 26 fractions\n      with respect to  two-year failure defined as a positive biopsy two years post treatment\n      completion or earlier evidence of biochemical or clinical failure."
        }, 
        "brief_title": "Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven prostate adenocarcinoma.\n\n               -  Gleason score 2-7 (reviewed by reference lab at UM).\n\n               -  Biopsy within one year of date of enrollment.\n\n          -  Clinical stage \u2264 T2 based on DRE and/or \u2264 T3a based on MRI (if done); N0-Nx; M0-Mx\n             (AJCC 7th Edition)\n\n               -  T-stage and N-stage determined by physical exam and available imaging studies\n                  (CT, and/or MRI of the pelvis; see section 4.5). For MRI, questionable\n                  extracapsular extension is permitted. To distinguish blood from tumor the ideal\n                  study would be to acquire T2, T1 noncontrast and T1 dynamic contrast enhanced\n                  sequence, although this is not required. A small amount of extracapsular\n                  extension is permitted, as long as it can be included in the CTV and the\n                  constraints are met.\n\n               -  M-stage determined by physical exam, CT or MRI. Bone scan not required unless\n                  clinical findings suggest possible osseous metastases.\n\n          -  PSA \u2264 15 ng/ml, obtained no greater than 3 months prior to enrollment.\n\n          -  Patients belonging in one of the following risk groups:\n\n               -  Low:\n\n                    -  Clinical stage*  T1-T2; Gleason \u2264 6, PSA \u2264 10 & <50% biopsy cores positive.\n\n               -  Intermediate:\n\n                    -  Clinical stage T2b-T2c; Gleason \u2264 6, PSA \u2264 10 & <50% biopsy cores positive.\n\n                    -  Clinical stage T1-T2; Gleason \u2264 6, PSA \u2264 10 & \u226550% biopsy cores positive.\n\n                    -  Clinical stage  T1-T2; Gleason = 7, PSA \u2264 10 & <50% biopsy cores positive\n                       or T1-T2; Gleason \u2264 6 & PSA >10 and \u226415 & <50% biopsy cores positive.\n\n                    -  MRI stage T3a with evidence of extraprostatic extension is allowed.\n\n               -  Clinical stage is based on digital rectal exam (DRE). Seminal vesicle invasion\n                  on MRI is not eligible. T1a should be permitted if subsequent peripheral zone\n                  biopsies show tumor.\n\n          -  Prostate volume: \u2264 80 cc.\n\n               -  Determined using: volume = \u03c0/6 x length x height x width.\n\n               -  Measured from CT or MRI \u226490 days prior to enrollment.\n\n          -  Zubrod performance status 0-1.\n\n          -  No prior total prostatectomy or cryotherapy of the prostate.\n\n               -  Prior suprapubic prostatectomy, transurethral resection and laser ablation are\n                  permitted.\n\n          -  No prior radiotherapy to the prostate or lower pelvis.\n\n          -  No implanted hardware or other material that would prohibit appropriate treatment\n             planning or treatment delivery, in the investigator's opinion.\n\n          -  No chemotherapy for a malignancy in the last 5 years.\n\n          -  No history of an invasive malignancy (other than this prostate cancer, or\n             nonmetastatic basal or squamous skin cancers) in the last 5 years.\n\n          -  No more than 4 months of androgen deprivation therapy (ADT) prior to enrollment. If\n             given, prior to enrollment, ADT cannot be continued during radiation or plan to\n             delivered after the completion of radiation therapy.\n\n          -  Patient must be able to have gold fiducial markers placed in the prostate (if on\n             anticoagulants, must be cleared by a primary care physician or cardiologist), or if\n             patient already has fiducial marker placed, they must be in accordance with the\n             protocol specifications (Section 4.2.2)\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n          -  Willingness to fill out quality of life/psychosocial forms.\n\n          -  Age >= 35 and =< 85 years.\n\n          -  IPSS (AUA) score \u226412\n\n        Exclusion Criteria:\n\n          -  Does not have a diagnosis of prostate adenocarcinoma.\n\n          -  Patient has clinical T3a or any evidence of T3b disease.\n\n          -  Patient has stage N1 or M1 disease.\n\n          -  Patients has a PSA of greater than 15 ng/ml.\n\n          -  Patient does not meet any of the risk groups outlined in section 3.1.4.\n\n          -  Prostate volume greater than 80 cc.\n\n          -  Zubrod performance status 2 or greater.\n\n          -  Prior total prostatectomy.\n\n          -  Prior radiation therapy to the prostate or lower pelvis.\n\n          -  Implanted hardware which limits treatment planning or delivery (determined by the\n             investigator).\n\n          -  Chemotherapy within the past 5 years.\n\n          -  Diagnosis of an invasive malignancy within 5 years (other than current prostate\n             cancer or non-metastatic basal or squamous skin cancers).\n\n          -  The use of more than 4 months of androgen deprivation therapy (ADT) prior to\n             enrollment, or plans for ADT to be continued during radiation to be delivered after\n             the completion of radiation therapy.\n\n          -  Inability to have gold fiducial markers placed in the prostate, or fiducial markers\n             already placed that are not in accordance with the protocol (Section 4.2.2)\n\n          -  Unwilling or inability to give informed consent.\n\n          -  Not willing to fill out quality of life/psychosocial questionnaires.\n\n          -  IPSS score > to 12.\n\n          -  Age < 35 and > 85 years."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794403", 
            "org_study_id": "UMIAMI-20110491"
        }, 
        "intervention": [
            {
                "arm_group_label": "Extended Hypofractionation Radiotherapy (EHRT)", 
                "description": "A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.", 
                "intervention_name": "Extended Hypofractionation Radiotherapy", 
                "intervention_type": "Radiation", 
                "other_name": "EHRT"
            }, 
            {
                "arm_group_label": "Accelerated Hypofractionation Radiotherapy (AHRT)", 
                "description": "A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.", 
                "intervention_name": "Accelerated Hypofractionation Radiotherapy", 
                "intervention_type": "Radiation", 
                "other_name": "AHRT"
            }, 
            {
                "arm_group_label": [
                    "Extended Hypofractionation Radiotherapy (EHRT)", 
                    "Accelerated Hypofractionation Radiotherapy (AHRT)"
                ], 
                "description": "All patients will have 3-4 gold fiducial seeds or tracking markers placed in the prostate under ultrasound guidance (biopsy) prior to treatment planning by MRI and/or CT.", 
                "intervention_name": "Fiducial Marker Placement", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Extended Hypofractionation Radiotherapy (EHRT)", 
                    "Accelerated Hypofractionation Radiotherapy (AHRT)"
                ], 
                "description": "The Expanded Prostate Cancer Index Composite Questionnaire-SF-12 (EPIC-SF-12) at after enrollment, prior to radiation therapy, and post-therapy at 6 weeks, 3 months, 9 months, 15 months, and then yearly to 5.25 years.\nMemorial Anxiety Scale for Prostate Cancer patients (MAX-PC) at after enrollment, prior to radiation therapy, and post-therapy at at 6 weeks, 3 months, 9 months, 15 months and then yearly to 5.25 years.\nInternational Prostate Symptom Index (IPSS) after enrollment, prior to radiation therapy, last week of therapy, and post-therapy at at 6 weeks, 3 months, and then every 6 months for 5.25 years.", 
                "intervention_name": "Quality of Life Questionnaires", 
                "intervention_type": "Behavioral", 
                "other_name": [
                    "The Expanded Prostate Cancer Index Composite SF-12 Questionnaire", 
                    "EPIC-SF-12", 
                    "Memorial Anxiety Scale for Prostate Cancer patients", 
                    "MAX-PC", 
                    "International Prostate Symptom Score", 
                    "IPSS"
                ]
            }, 
            {
                "arm_group_label": [
                    "Extended Hypofractionation Radiotherapy (EHRT)", 
                    "Accelerated Hypofractionation Radiotherapy (AHRT)"
                ], 
                "description": "Prostate biopsy at 2 - 2.5 years post completion of all therapy. Additional as needed.", 
                "intervention_name": "Prostate Biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "Prostate Biopsy"
            }, 
            {
                "arm_group_label": [
                    "Extended Hypofractionation Radiotherapy (EHRT)", 
                    "Accelerated Hypofractionation Radiotherapy (AHRT)"
                ], 
                "description": "Biomarker analysis of the DNA content (image analysis) and immunohistochemical analyses of Ki-67/MIB-1, p53, bcl-2, bax, MDM2, and PKA in biopsy tissue.", 
                "intervention_name": "Biopsy Tissue for Biomarkers", 
                "intervention_type": "Genetic"
            }, 
            {
                "arm_group_label": [
                    "Extended Hypofractionation Radiotherapy (EHRT)", 
                    "Accelerated Hypofractionation Radiotherapy (AHRT)"
                ], 
                "description": "Blood and urine samples. Four tubes of approximately 10 cc of blood each will be collected prior to treatment. Approximately 50 mL of urine will be collected.", 
                "intervention_name": "Biofluids for proteomics and genomics studies", 
                "intervention_type": "Genetic"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prostate Cancer", 
            "Prostate", 
            "Radiation Therapy", 
            "Hypofractionation  Radiotherapy", 
            "Extended Hypofractionation  Radiotherapy", 
            "Accelerated Hypofractionation  Radiotherapy", 
            "AHRT", 
            "EHRT"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "contact": {
                "email": "mabramowitz@med.miami.edu", 
                "last_name": "Matthew C Abramowitz, MD", 
                "phone": "305-243-4200"
            }, 
            "contact_backup": {
                "email": "sylvester@emergingmed.com", 
                "last_name": "University of Miami Sylvester Comprehensive Cancer Center", 
                "phone": "866-574-5124"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "University of Miami Sylvester Comprehensive Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Matthew Abramowitz, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Saleem Umar, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Radka Stoyanova, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Javier Casillas, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charles Lynne, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Margaret Byrne, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Study of Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer", 
        "overall_official": [
            {
                "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
                "last_name": "Matthew Abramowitz, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
                "last_name": "Alan Pollack, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compare the two-year failure rates (biochemical or clinical failure, or positive biopsy) between the treatment arms (AHRT and EHRT) using a noninferiority margin of 12%.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Compare acute toxicity rates of AHRT and EHRT.", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Compare the efficacy of AHRT with EHRT for the treatment of low and early intermediate risk prostate cancer, where efficacy is defined by biochemical failure using Phoenix (Nadir+2) definition or clinical failure.", 
                "measure": "Compare Efficacy of AHRT with EHRT", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Compare AHRT and EHRT with respect to prostate cancer mortality and overall survival.", 
                "measure": "Compare AHRT and EHRT overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Compare AHRT and EHRT with respect to quality of life (QOL), including erectile dysfunction rates, in generic and organ-specific domains.", 
                "measure": "Compare AHRT and EHRT quality of life", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Rates of ASTRO-defined biochemical failure.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Examine the relationship of biomarkers from pretreatment diagnostic tissue and blood to the efficacy endpoints, toxicity and QOL.", 
                "measure": "Relationship of biomarkers from pretreatment diagnostic tissue and blood to the efficacy endpoints, toxicity and QOL.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To compare the rates of late-occurring grade 2 or greater G.I. or GU toxicity.", 
                "measure": "Rates of late-occurring grade 2 or greater GI/GU toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Evaluate the comparative effectiveness of each treatment regimen.", 
                "measure": "Effectiveness of AHRT and EHRT", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Examine the cost utility of each treatment regimen.", 
                "measure": "Cost utility of AHRT and EHRT", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University of Miami Sylvester Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami Sylvester Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}